Nasal Packing Versus Intravenous Dexmedetomidine in Turbinate Surgeries

Kafrelsheikh University60 enrolled

Overview

Comparing of nasal packing DEX and IV DEX for controlling the intraoperative bleeding after turbinate surgery.

Dexmedetomidine (DEX) is a highly selective α2 adreno-receptor agonist with higher affinity to a2 adreno-receptor than clonidine, and this makes DEX primarily sedative and anxiolytic. The elimination half-life of DEX (t1/2b) is 2 h and the redistribution half-life (t1/2a) is 6 min, and this short half-life makes it an ideal drug for intravenous titration. Potentially desirable effects include decreased requirements for other anesthetics and analgesics.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Nasal Packing Dexmedetomidine Turbinate

Interventions

Nasal packing DexmedetomidineDRUG

patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.

Intravenous DexmedetomidineDRUG

patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 to 65 years * Both sexes * American Society of Anesthesiologists (ASA) physical status classification I or II. * Undergo turbinate surgery Exclusion Criteria: * Patients with a body mass index \> 30 kg/m2 existing or recent significant disease. * Contraindications to the use of dexmedetomidine . * History or presence of a significant disease significant cardiovascular disease risk factors. * Significant coronary artery disease or any known genetic predisposition. * History of any kind of drug allergy, * Drug abuse. * Clinically significant abnormal findings in physical examination, electrocardiographic (ECG) or laboratory screening. * Known systemic disease requiring the use of anticoagulants, * Patients with a history of previous turbinate surgery.

Locations (1)

Karelsheikh University Hospital

Kafr ash Shaykh, Karelsheikh, Egypt

Outcomes

Primary Outcomes

Amount of intraoperative blood loss

Measuring the volume of suctioned blood in graduated columns, which will contain an anticoagulant to prevent coagulation and clotting and weighing gauze sponges.

Time frame: Intraoperative up to 6hours

Secondary Outcomes

Pain score

Visual analogue scale (VAS) (0, no discomfort and no pain; 10, a high level of discomfort and maximum pain)

Time frame: 24 hours postoperative

Quality of intraoperative surgical field

Quality of intraoperative surgical field during after turbinate surgery will be evaluated by the surgeons by rating the amount of bleeding according to a 6-point scale by Formmer's scores of surgical field quality (0= no bleeding; 1= bleeding, so mild it was not even a surgical nuisance; 2= moderate bleeding, a nuisance but without interference; 3= moderate bleeding that moderately compromised surgical; 4= bleeding, heavy but controllable, that significantly interfered; 5= massive uncontrollable bleeding)

Time frame: Intraoperative up to 6hours

Patient's general satisfaction

Patients' satisfaction will be measured immediately postoperative and using a five-point Likert scale consisting of "very dissatisfied," "dissatisfied," "unsure," "satisfied," and "very satisfied.

Time frame: 24 hours postoperative

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.